Autopsy report · NCT04336943
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Cause of deathSlow enrollment
“Slow accrual”
Life of this trial
- Registered 1 year before it started.
- Ran for about 4 years 2 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Conditions
- Biochemically Recurrent Prostate Carcinoma; Prostate Adenocarcinoma
- Interventions
- Durvalumab; Olaparib; Quality-of-Life Assessment; Questionnaire Administration
- Participants
- 6
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.